U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07526597) titled 'Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors' on April 06.
Brief Summary: This Phase II hybrid decentralized multicenter study examines the outcomes of stopping Bruton tyrosine kinase inhibitor (BTKi) therapy in patients with chronic lymphocytic leukemia (CLL) who have remained in remission for at least two years. The primary objective is to determine how long patients remain free from disease progression or death after discontinuing treatment, measured as event free survival.
The study also evaluates whether stopping BTKi therapy leads to improvements in quality of life and red...